Drug Trial Radar · NCT05584137
Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients with MCRC
Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
2
Actual
Start
Jun 15, 2023
Primary completion
Dec 31, 2023
Study completion Dec 31, 2023
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a phase II study to evaluate the efficacy, safety and tolerability of HLX26 and HLX10 in the treatment of patients with metastatic colorectal carcinoma that had received 3 prior therapies.
Conditions
- Colorectal Cancer Metastatic
Interventions
HLX26Drug
Humanized Anti-Lymphocyte Activation Gene-3 Monoclonal Antibody
HLX10Drug
Humanized Anti-Programmed Death-1 Monoclonal Antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) (the first stage)Time frame: from day1 to day 21
- Maximum Tolerated Dose (MTD) (the first stage)Time frame: from day1 to day 21
- Objective Response Rate (ORR) per RECIST 1.1 as Assessed by Investigator (the second stage)Time frame: approximately up to 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.